/BTMD
BTMD Stock - biote Corp.
Healthcare|Medical - Care FacilitiesNASDAQ
$2.78+1.09%
+$0.03 (+1.09%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.29
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.74
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+210.1%upside
Target: $8.62
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BTMD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.75 – $2.81
TARGET (TP)$8.62
STOP LOSS$2.56
RISK/REWARD1:26.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.16
52W High$6.36
52W Low$2.31
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $197.19M | $185.36M | $164.96M | $139.40M | $116.57M |
| Gross Profit | $139.06M | $127.48M | $110.38M | $90.58M | $71.64M |
| Gross Margin | 70.5% | 68.8% | 66.9% | 65.0% | 61.5% |
| Operating Income | $31.61M | $28.66M | $-60,722,000 | $34.56M | $31.78M |
| Net Income | $3.16M | $3.32M | $-969,000 | $32.62M | $29.16M |
| Net Margin | 1.6% | 1.8% | -0.6% | 23.4% | 25.0% |
| EPS | $0.09 | $0.13 | $0.16 | $-0.87 | $3.85 |
Company Overview
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
83%
Hold / Neutral
1
17%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish1 Neutral/Bearish
Price Targets
$8
Average Target
↑ 196.8% Upside
Now
$4
Low
$8
Average
$11
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 7th 2025 | B. Riley Securities | Downgrade | Neutral | $4 |
| December 16th 2024 | Craig Hallum | Initiation | Buy | - |
| February 20th 2024 | B. Riley Securities | Initiation | Buy | $9 |
| February 1st 2024 | Jefferies | Initiation | Buy | - |
| June 24th 2022 | Cowen | Initiation | Outperform | $11 |
| June 23rd 2022 | ROTH Capital | Initiation | Buy | $9 |
Earnings History & Surprises
BTMDBeat Rate
86%
Last 14 quarters
Avg Surprise
+161.6%
EPS vs Estimate
Beats / Misses
12/2
Last 12 quarters
Latest EPS
$0.22
Q4 2025
EPS Surprise History
Q1 24
+125.0%
$0.18vs$0.08
Q2 24
+360.0%
$0.23vs$0.05
Q3 24
+55.6%
$0.14vs$0.09
Q4 24
+266.7%
$0.33vs$0.09
Q1 25
+11.1%
$0.10vs$0.09
Q2 25
+33.3%
$0.08vs$0.06
Q3 25
+66.7%
$0.10vs$0.06
Q4 25
+340.0%
$0.22vs$0.05
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 11, 2026 | $0.02 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.05 | $0.22 | +340.0% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.06 | $0.10 | +66.7% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.06 | $0.08 | +33.3% | ✓ BEAT |
Q1 2025 | Mar 12, 2025 | $0.09 | $0.10 | +11.1% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $0.09 | $0.33 | +266.7% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $0.09 | $0.14 | +55.6% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $0.05 | $0.23 | +360.0% | ✓ BEAT |
Q1 2024 | Mar 12, 2024 | $0.08 | $0.18 | +125.0% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $0.08 | $-0.11 | -237.5% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $0.10 | $0.44 | +340.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $0.09 | $0.94 | +944.4% | ✓ BEAT |
Q1 2023 | Mar 28, 2023 | $0.14 | $0.18 | +28.6% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $0.14 | $-0.09 | -164.3% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $0.14 | $0.27 | +92.9% | ✓ BEAT |
Q2 2022 | May 21, 2022 | — | $1.23 | — | — |
Q2 2022 | Apr 7, 2022 | — | $0.72 | — | — |
Q4 2021 | Nov 24, 2021 | — | $1.13 | — | — |
Q3 2021 | Aug 17, 2021 | — | $1.29 | — | — |
Frequently Asked Questions about BTMD
What is BTMD's current stock price?
biote Corp. (BTMD) is currently trading at $2.78 per share. The stock has moved +1.09% today.
What is the analyst price target for BTMD?
The average analyst price target for BTMD is $8.62, based on 1 analyst.
What sector is biote Corp. in?
biote Corp. operates in the Healthcare sector, specifically within the Medical - Care Facilities industry. The company is traded on the NASDAQ exchange.
What is BTMD's market cap?
biote Corp. has a market capitalization of $0.13 billion, making it a small-cap company.
Does BTMD pay dividends?
No, biote Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABOS
Acumen Pharmaceuticals, Inc.
$2.15
Mkt Cap: $0.1B
ACTU
Actuate Therapeutics Inc
$6.98
Mkt Cap: $0.2B
ANIK
Anika Therapeutics, Inc.
$9.57
Mkt Cap: $0.1B
INO
Inovio Pharmaceuticals, Inc.
$2.28
Mkt Cap: $0.1B
JYNT
The Joint Corp.
$9.00
Mkt Cap: $0.1B
LUCD
Lucid Diagnostics Inc.
$1.12
Mkt Cap: $0.1B
MCRB
Seres Therapeutics, Inc.
$14.98
Mkt Cap: $0.1B
SCLX
Scilex Holding Company
$14.35
Mkt Cap: $0.1B
SPRO
Spero Therapeutics, Inc.
$2.32
Mkt Cap: $0.1B
VOR
Vor Biopharma Inc.
$12.41
Mkt Cap: $0.1B
Explore stocks similar to BTMD for comparison